We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Expands Sources for Cannabis Clinical Research

FDA Expands Sources for Cannabis Clinical Research

January 25, 2023

The FDA has finalized guidance on trials of human drugs containing cannabis and cannabis-derived compounds, offering updated direction on federally authorized sources for cannabis.

The National Institute on Drug Abuse’s (NIDA) Drug Supply Program (DSP), which provides cannabis grown under contract by the University of Mississippi, was formerly the only domestic, federally legal source for cannabis containing more than 0.3 percent delta-9 tetrahydrocannabinol (THC) for use in clinical research. But this has changed since the agency’s 2020 draft guidance, and sponsors and investigators now have multiple sourcing options.

According to the final guidance, researchers may now use non-NIDA DSP sources of cannabis that contain more than 0.3 percent delta-9 THC on a dry weight basis (a THC level that renders the cannabis a Schedule 1 controlled substance) as well as non-NIDA DSP sources for cannabis at or under the 0.3 percent threshold, so long as the FDA deems the source(s) to be of adequate quality. They may also still use the NIDA DSP for sourcing cannabis stronger than the 0.3 percent delta-9 THC threshold, the guidance says.

A list of growers of Schedule 1 cannabis cleared by the Drug Enforcement Administration (DEA) is located online and can be accessed through the guidance.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

  • MedTrace Receives U.S. Patent for Heart Modeling Method

  • NICE Recommends Epidyolex for Tuberous Sclerosis Complex Seizures

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing